Prions

Published by: RI Technologies

Published: May. 8, 2008 - 271 Pages

Table of Contents

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

1. Prions

Introduction

Exhibit 1: Mammalian Agents of Spongiform Encephalopathies, ICTVdb Code, Disease Name, Natural Host, Prion Name and PrP Iso Form

General Definitions

Genetic Disorder

Sporadic Disease

Itarogenic Disease

History of BSE

Animal Feed

Animal Feed Regulations

Concern for Quality of Feed Ingredients with Increase in BSE

around the World

Eurofins Forms Strategic Alliance with VLA in UK to Maintain Feed Safety

Plan on Ban of certain Cattle Material from Medical Products to

Protect Against BSE

New Theory Suggests the Origin of Mad Cow Disease to be from Human Beings

Role of WHO in TSE Control

Role of OIE

2. Global Market Analysis

Exhibit 2: Prion Deactivation Technologies (2005-2012) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 3: Prion Reduction Filters (2005-2012) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 4: BSE Post Mortem Testing (2005-2012) - Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Exhibit 5: List of Major Global Companies

3. Regional Market Analysis

North America

Analysis by Prion Deactivation Technologies

Exhibit 6: Prion Deactivation Technologies (2005-2012) - North American Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 7: Prion Reduction Filters (2005-2012) - North American Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 8: BSE Post Mortem Testing (2005-2012) - North American Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

US Allocation of Funds for Food Safety and BSE Research

Harmonization of BSE Management Policies by United States, Canada, and Mexico

Europe

Analysis by Prion Deactivation Technologies

Exhibit 9: Prion Deactivation Technologies (2005-2012) - European Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 10: Prion Reduction Filters (2005-2012) - European Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 11: BSE Post Mortem Testing (2005-2012) - European Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Exhibit 12: Number of Confirmed BSE Cases in Europe (2003-2007)

European Policies on BSE

The Netherlands

New Case of Mad Cow Disease Reported in The Netherlands

Slovenia

Slovenian Authorities Confirm BSE Case Findings

Austria

August 2005, Third Case of Mad Cow Reported in Austria

Switzerland

Swiss Beef Industry Awarded for Managing BSE

EU Commission’s Latest Proposal Reduces BSE Testing Costs

Japan

Analysis by Prion Deactivation Technologies

Exhibit 13: Prion Deactivation Technologies (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 14: Prion Reduction Filters (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 15: BSE Post Mortem Testing (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Rest of World

Analysis by Prion Deactivation Technologies

Exhibit 16: Prion Deactivation Technologies (2005-2012) - Rest of World Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 17: Prion Reduction Filters (2005-2012) - Rest of World Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 18: BSE Post Mortem Testing (2005-2012) - Rest of World Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

III. PRODUCT/TECHNOLOGY RESEARCH

Introduction

History

Prions Formation

Structure and Organization of Prions

Special Characteristics of Infectious Proteins

Isoforms

PrPC

PrPSc

PrP’s Role in Long-Term Memory

Hypothesis

Characteristics of Prions

Exhibit 19: Comparison of General Characteristics of Classic Virus and Prions

Prion Biosynthesis

Prions Replication

Prion Strains

Species Barrier

Diseases Caused by Prions

Exhibit 20: Diseases caused by Prions in Animals

Characteristics of Transmissible Spongiform Encephalopathy (TSE)

Treatment of TSEs

Transmission and Causes of Prion Diseases

Prion Transmission and Propagation Modes

Metallic Poisoning

Viral Possibilities

Genetics

Sterilization

Prions in Yeast and Other Fungi

Prions - Proteins that Transmit the Mad Cow Disease

Introduction

Relationship between CJD and BSE

Mechanism of the Prion Diseases

Unsolved Puzzle

Effectiveness of Quinacrine for Treating Creutzfeldt-Jakob Disease

Analysis of Pentosan Polysulphate for Treating Prion Diseases

The Difficulty Posed by Blood Brain Barrier

Risks Associated with PPS

Efficacy Evaluation of Intraventricular PPS Administration

Species Barriers for Prions

TSE

Spreading of TSE

Efforts to Control TSE Related Diseases

Effect of TSE Related Diseases on Biopharmaceutical Industry

Development of In Vitro Diagnostics Polyclonals Free from Pathogen of Scrapie and BSE

Genotype

Extensive Monitoring of Disease Pathogens

Conclusion

Transmissible Spongiform Encephalopathy (TSE)

Exhibit 21: List of Prion Diseases and Pathogenesis in Humans

Exhibit 22: List of Prion Disease and Pathogenesis in Animals.

Characteristics of TSE

Genetics

Epidemiology

Possible Cure or Vaccine

Research to Treat Prion Diseases

Bovine Spongiform Encephalopathy (BSE)

Source of the Epidemic

Cause

Cases of BSE

Measures to Prevent the Spread of BSE

Prion and BSE - Mad Cow Disease

Mechanism of Conversion of PrPC to PrPSc

Reported Cases of BSE

BSE Testing

The Detection of BSE in Rodents Increases the Need for Research

Regulations

BSE/TSEs Testing Regulations Imposed by European Union

Transmissible Mink Encephalopathy (TME)

TME Related Diseases

Clinical Characteristics of TME Infected Animals

Diagnosis

Prevalence of the Disease

Scrapie

History

Introduction

Epidemiology and Transmission

Clinical Signs

Wool Manufacturing Process - An Effective Route of BSE Propagation

Research

Diagnosis of Scrapie

Immunohistochemical (IHC) Detection

Capillary Electrophoresis Immunoassay

Eradication Program

Exhibit 23: Number of Scrapie Cases Reported in Great Britain (1993-2003)

Scrapie Cases Reported

Feline Spongiform Encephalopathy (FSE)

Introduction

Cause

Common Breeding Age and Occurrence

Common Symptoms

Main Complications Pertaining to the Disease

Methods Employed for Diagnosis of the Disease

Treatment

Prognosis

Action to be taken in Case of Confirmation of the Disease

Chronic Wasting Disease (CWD)

History

Major Consequences of CWD Prevalence

Causative Agent

Clinical Features

Clinical Duration

Characteristics of Chronic Wasting Disease

Diagnosis

Epidemiology

Distribution

Control Strategies

Kuru

History

Introduction

Definition

Transmission

Diagnosis

Treatment

Research

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

Introduction

Cause

Symptoms

Prognosis

Creutzfeldt - Jakob disease

Introduction

Three Major Types of CJD

Sporadic CJD

Hereditary CJD

Acquired CJD

Symptoms of CJD

Clinical Diagnosis of CJD

Treatment

Prions the Causative Agent of CJD

Transmission of CJD

Precautions to Control Spreading of the Disease

Research

CJD-Types and Characteristics

Sporadic CJD

Definition

Variant CJD

vCJD

Definition

Origin of vCJD

Symptoms of vCJD

Differences Between spCJD and vCJD

Differences Between Classic and Variant CJD

Prevalence of vCJD

Genetic CJD

Iatrogenic CJD

Definition

Diagnosis of CJD

EEG

Biomarkers

14-3-3 protein.

Sensitivity and Specificity of 14-3-3 Protein Vary With the Form of CJD

SpCJD

vCJD

iCJD

Familial CJD

Metallothionein

Laminin Receptor Protein / Laminin

Sporadic CJD

The EEG

Cerebrospinal Fluid 14-3-3 Analysis

Magnetic Resonance Imaging

Variant CJD

Magnetic Resonance Imaging

Tonsil Biopsy

CSF 14-3-3

Exhibit 24: Number of Reported Cases of vCJD by Country.

Genetic CJD

Iatrogenic CJD

Exhibit 25: Referrals of Suspect CJD, Deaths of Definite and Probable CJD in the United Kingdom

CJD Control Measures in United Kingdom and United States

About Centers for Disease Control and Prevention

Fatal Familial Insomnia (FFI)

Introduction

History

Pathophysiologyof Disease

Disease Progression

Treatment

Relation of FFI with Other Prion Diseases

Common Symptoms and Time Duration Observed in FFI

Diagnostic Procedures for Detection of FFI

Post-mortem Examination

Technologies in Detection of Prions

Immunocapillary Electrophoresis:

Merits and Limitations of ICE as a Screening Test for Prion Diseases

Principle of ICE

Sample Source

ICE Methodology

Parameters

Sensitivity of ICE

Limitations and the Present Status of Screening Test

Heartbeat Clue to Diagnosing vCJD

Conventional Technique

Conformation Dependent Immunoassay

Merits of CDI

Sensitivity

Quantification

Rapid Screening

Early Diagnosis

Other Benefits

Immunoblot (IB)

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis and Immunoblotting

Immunoblots

Immunoblot Analysis

Histopathology and Immunohistochemistry

Immunohistochemistry

Protein Misfolding Cyclic Amplification (PMCA)

The PMCA Assay

Amplification of rPrPC to rPrPSc in vitro

Amplification Technique Improves Prospects for Diagnostic Tests

Protein-Based PCR for Prion Diseases

Western Blot Assay for TSE

PrP.sup.sen and PrP.sup.res

Electrophoretic Pattern of PrP

Western Blot Assay for PrP

Synthetic Ligands

A Protein-Binding Ligand System for Prion Disease Detection

Scope of the Disease Family

Postmortem Prion Disease Testing

Blood Testing for the Prion Disease Agent

Immuno-PCR

Bio Markers for Detection of Prions (Surrogate Markers)

Prion Infection

Surrogate Markers

Other Assays for Diagnosis of Prion Diseases

Platelia Test (ELISA, BioRad)

Detection

CDI (Inpro)

Histoblot

Paraffin-Embedded Tissue (PET) Blot

ELISA and DELFIA

Rapid Assay

Advantages

RNA Aptamers and Prion Proteins

Aptamers

Prion Protein Binding RNA Aptamer

Interaction of RNA Aptamers with PrPc

RNA Aptamer as a Diagnostic and Therapeutic Agent

Aptamer and Mutations

Transmissible Diseases in Human Plasma

Gradiflow™ Apparatus and its Efficacy

The isolation Process

Final Result

Conclusion

Prion Vaccines

Prion Disease Prevention through Vaccine in Mice

Vaccination

Promising Vaccines against Prion Disease

Toxic Clumps

Gut Reaction

Growth Trends - Global Prion Deactivation Technologies

Exhibit 26: Global* Market for Prion Deactivation Technologies: Geographic Regions (North America, Japan, Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Prion Inactivation and Decontamination Techniques

Introduction

General Methods of Decontamination

Facility Issues

Device Issues

Prion Inactivation

Prions and its Deactivation Techniques

Exhibit 27: Ineffective or Unreliable Methods of Eradicating Prions

Validation Studies to Analyze Sanitation Practices

Enzyme-Detergent Method for Effective Sterilization of Prion on Surgical Steel

Latest Methodologies Restricting the Infections Caused by

Prion-Contaminated Medical Appliances

Introduction

Available Alternatives or Methodologies

Conditions Normally Used for Inactivating Prions

Conclusion

Analysis

Novel Methods to Restrict Decontamination of Surgical Instruments

Techniques for Inactivation of Prions in Reusable Instruments and Surfaces

Standard Gravity Steam Sterilization Techniques for Treatment of Prion Infections

Methods Effective in Limiting Prion Infectivity

Pre Vacuum Steam Sterilization

Conventional Methods for Inactivation of Prions

Use of NaOH and NaOCl for Chemical Disinfection

Application of Maillard Reaction to Minimize Prion Activation

Clearence Studies

Introduction

Prion Clearence Studies

Prion Inactivation and Removal

Creutzfeldt - Jakob Disease

Bovine Components

Sanitization of Prion

EMEA Clearance

ViruSure

Effective Mode Prion Clearance

The Regulatory Environment

The Nature of the Agent

Spiking Agents

Yardsticks for Clearance

Investigative Steps

Growth Trends - Global Prion Reduction Filters

Exhibit 28: Global* Market for Prion Reduction Filters: Geographic Regions (Japan, North America, Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Evaluation of the Efficacy of Prion Reduction Filters

Core Concerns

TSE Transmission via Blood

Filters to Facilitate Reduction in Prion Proteins

The Effectiveness of the Pall Corporation Filter

UKBS Approach to of Filters

Experimental Models for Endogenous Infectivity in Blood

Donor Species

Prion Strain

Method to Detect Infectivity/PrPSc

Advice Sought From the Committee

Approach to Prevent and Control the Spread of Prion Diseases in Human Beings

Methods to Control the Cause of BSE and Scrapies

Methods for Controlling the Transmission of Prions via Human Plasma Derivatives

Antemortem Prion Diagnosis

Antemortem Diagnosis of CWD (Chronic Wasting Disease)

Development of Aptamer Beacons for Ante-mortem Diagnosis of Chronic Wasting Disease

Antemortem Diagnosis of vCJD

Molecular Diagnosis of vCJD through Ante-mortem Tonsil Biopsy

Antemortem Diagnosis of BSE

Ante-mortem Assays for Infectious Prion Protein

Evaluation Protocol

Evaluation Process

Criteria for Submission of Dossier

Pre-Evaluation Assessment

Criteria for Admission to Full Evaluation

Summary

Growth Trends - Global BSE Post Mortem Testing

Exhibit 29: Global* Market for BSE Post Mortem Testing: Geographic Regions (Japan, North-America, Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included)

Post Mortem BSE Testing

IDEXX HerdChek® Bovine Spongiform Encephalopathy Antigen Test Kit EIA

Overview

Description and Principles

Parts of the Kit

Sampling and Preparation

Step 1

Step 2

Step 3

Step 4

Preparation of Reagents

Wash Solutions 1 and 2

Plate Diluent Component 2

Working Plate Diluent

Negative and Positive Controls

HRPO-Conjugated Anti-PrP Antibody Solution

Acid Stop Solution

Test Procedure

Assay Protocols

Sample Dilution in Working Plate Diluent

Use of Plate Shaker for Sample Incubation Protocols - Short and Ultra-short

Results

Precautions

Safety Information

Post Mortem BSE Testing

Prion Diseases

Post-Mortem Tests

Enfer TSE assay

Principle

Buffers

Merits

Prionics®-Check WESTERN

Method

Merits

Prionics®-Check LIA

Method

Merits

Prionics®-Check PrioSTRIP

Method

Merits

Ante-Mortem Tests

Post Mortetm CWD Prion Diagnosis

Prions: Antigen-Capture Enzyme-Linked Immunoassay

Principle of Enzyme-Linked Immunoassay

Protocol of EIA

Merits of EIA

Efficacy of EIA

Collagen

Structural Protein

Function of Collagen in the Human Body

Safety Measures Offered by Collagen

Clinical Perseverance of Collagen Product

Enhanced Performance

Superior Flexibility

Products Derived from Collagen and its Multiple Biomedical Applications

Procedure Followed in the Extraction of Collagen

Properties and Characteristics of Atelocollagen

Additional Characteristics of Atelocollagen

Processing of Atelocollagen to Desired Configurations

Mutable Characteristics of Available Atelocollagen

Superior Quality of KOKEN Atelocollagen

KOKEN Atelocollagen is Absolutely Safe

Application of Collagen in Various Biomedical Applications

Application in Clinical Medicine

Tissue Culture Research

Cosmetics

KOKEN Special-Purpose Atelocollagen Design

Bovine Milk and Milk Products

TAFS position paper on the Safety of Bovine Milk and Bovine Milk Products

The Relationship of Prions, PrPc and PrPSc

Bovine Milk Not a Route of BSE Transmission

Ovine Milk and TSE

Prions Risk Assesment

Measuring Risks Related to Prions

Prion Diseases Management Policies

Health Control Policies in UK

European Union and BSE controls

Exhibit 30: Preventive Measures against the Introduction and Spread of BSE in the EU

Japan and BSE

Preface

FDA’s Qualitative Risk Assessment

Proteins from Cattle in Cosmetics

Modes for Transmission of Prions through Cosmetics

Identification of Hazard

Dose-Response Assessment

Characterization of Risk

Inferences

Prions: Animal Bioassays and Cell Culture Assays

Mechanism of Prion Formation

Animal Bioassays

Cell Culture Bioassays

Genetic Engineering Tools

Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathies

via Human and Veterinary Medicinal Products

Regulatory Compliance

Risk Assessment

Legal Aspects

Clarification of Note for Guidance

Scope of the Note for Guidance

Relevant Animal Species

Materials

Seed Lots, Cell Banks and Routine Fermentation/Production

General Considerations

Scientific Principles for Minimising Risk

Source Animals

Geographical Sourcing

Bovine Materials

European Commission Scientific Steering Committee Classification

Sheep and Goats (Small Ruminants)

BSE Negligible Risk (Closed) Bovine Herds

Parts of Animal Bodies, Body Fluids and Secretions as Starting Materials

Age of Animals

Manufacturing Process

Cleaning Process

Validation

Risk Assessment of Materials or Substances Used in the Manufacture and Prepratation of a

Medicinal Product in the Context of Regulatory Compliance

Risk/Benefit Evaluation

Specific Considerations

Collagen

Gelatin

Bovine Blood Derivatives

Tallow Derivatives

Animal Charcoal

Milk and Milk Derivatives

Wool Derivatives

Amino Acids

Product Trends

A New Fluorescent Molecule Effective in Diagnosing Prion Disease

New Test to Detect Bovine Spongiform Encephalopathy

Hematech - Company Develops New BSE Resistant Cow

IV. MARKET DYNAMICS

World Cattle Demographics

Exhibit 31: World Cattle Population (2000-2006) - By Geographic Regions for North America, Europe, Japan and Rest of World in Million Head (Graphical Representation Included)

1. Market Overview

Prion Deactivation Technologies - Global Market Analysis

Exhibit 32: Prion Deactivation Technologies (2005-2012) - Global Market Analysis (Current and Future) by Geographic Regions for Europe, Japan, North America and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 33: Prion Deactivation Technologies (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Regions for Europe, Japan, North America and Rest of World (Graphical Representation Included)

Prion Reduction Filters - Global Market Analysis

Exhibit 34: Prion Reduction Filters (2005-2012) - Global Market Analysis (Current and Future) by Geographic Regions for Europe, North America, Japan and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 35: Prion Reduction Filters (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for Europe, North America, Japan and Rest of World.

BSE Post Mortem Testing - Global Market Analysis

Exhibit 36: BSE Post Mortem Testing (2005-2012) - Global Market Analysis (Current and Future) by Geographic Regions for Europe, North America, Japan and Rest of World in US$ Million (Graphical Representation Included)

Exhibit 37: BSE Post Mortem Testing (2006, 2009 and 2012) - Percentage Breakdown of Global Market Value by Geographic Region for Europe, North America, Japan and Rest of World

2. Major Companies in Prions Industry

Abbott Laboratories (USA)

Altegen, Inc. (USA)

Beckman Coulter, Inc. (USA)

Bio-Rad Laboratories, Inc. (USA)

Chronix Biomedical GmbH (Germany)

Clinical Data, Inc. (USA)

Covance, Inc. (USA)

Eurofins Scientific SA (France)

Eurogentec SA (Belgium)

GeneThera, Inc. (USA)

Genencor International, Inc. (USA)

IdentiGEN Ltd. (Ireland)

IDEXX Laboratories, Inc. (USA)

Meridian Life Science, Inc. (USA)

Microsens Biotechnologies (UK)

Millipore Corporation (USA)

Novartis AG (Switzerland)

Pall Corporation (UK)

Prionics AG (Switzerland)

ProMetic Life Sciences, Inc. (Canada)

Proteome Sciences PLC (UK)

Protherics PLC (UK)

ScheBo® • Biotech AG (Germany)

VMRD, Inc. (Veterinary Medical Research & Development) (USA)

3. Major Activities in Prions Industry

HemoBioTech Acquires Pathogen Clearance Technology from Texas University

Mad Cow Disease Risk Elimination from Donated Blood - Pioneered by Scot Doctors

Scrapie Prions Detected by Amorfix in Blood from Asymptomatic Sheep

Certain Cattle Parts Banned from Animal Feed by the FDA

ProMetic to Acquire Pathogen Removal and Diagnostic Technologies Inc

Mysteries of Neurodegenerative Diseases Uncovered by the Royal Veterinary College

British Blinded Panel of Spiked Human Blood Samples Results Released by Amorfix

Resin for Prion Elimination in Plasma product for Biopharmaceutical Application

Upgraded by ProMetic

Human Clinical Trials for P-Capt® Prion Filter Successfully Completed

The Concentration Technology of PRDT Magnifies Sensitivity of Diagnostic Tests for BSE

ProMetic BioTherapeutics Signs Agreement with Kedrion to Develop Multiple Hyperimmunes

Prionics Lelystad Launched in Netherlands

Eurofins Acquires Analycen

GeneThera and IZSLER in Collaboration Agreement

ProMetic Announces New Filter Product to Detect BSE in Cattle

Expanded Marketing of Mad Cow Disease Testing Kits by GeneThera

Private Testing for Mad Cow Disease Permitted by Court

Vita-Tech Acquired by IDEXX

IDEXX Acquires Critical Care Division of Osmetech

Covance now Becomes the Only Provider of Neuroscience Gold Standard Antibodies

to Treat Alzheimer’s and Prions Diseases

Rapid BSE Diagnosis Facility of IdentiGEN Awarded ISO Certification

Abbott to Provide Blood Screening Facility Along with Four Important

Tests to American Red Cross

Newly Developed Prion Capture Filter Receives CE Mark

IDEXX Acquires Golden Veterinary Laboratory in South Africa

New Acquisition Results in Comprehensive Antibody Products and Services

Prionics Buys CEDI Diagnostics, Creates New Strategic Alliance with World Class

Science Innovation Center

Prionics Buys Pfizer Animal Health’s Diagnostic Products

IDEXX Acquires ITS Innovative Technologies and Systems

Covance Acquires GFI Research Center; Phase I Clinical Capacity Now Increased

Pall Corporation in Collaboration with Fresenius Kabi for Speedy Implementation of

Prion Reduction Technology

CFIA Endorses New BSE Test

Strategic Alliance Between ProMetic and Top Meadow to Develop New Diagnostics

for the Easy Detection of BSE

Pall Launches Filter System to Eliminate Prions from Blood

Pall Corporation in Global Supply Agreement with Gambro BCT for Leukoreduction Filters

HerdChek® BSE Antigen EIA Test Kit from IDEXX Approved by European Commission

Euroflow Acquired by Pall Corporation

4. Regional Market Analysis

A. NORTH AMERICA

Analysis by Prion Deactivation Technologies

Exhibit 38: Prion Deactivation Technologies (2005-2012) - North American Market Analysis (Current and Future) by Geographic Region for Canada and United States in US$ Million (Graphical Representation Included)

Exhibit 39: Prion Deactivation Technologies (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for Canada and United States (Graphical Representation Included)

Analysis By Prion Reduction Filters

Exhibit 40: Prion Reduction Filters (2005-2012) - North American Market Analysis (Current and Future) by Geographic Region for Canada and United States in US$ Million (Graphical Representation Included)

Exhibit 41: Prion Reduction Filters (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for Canada and United States (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 42: BSE Post Mortem Testing (2005 - 2012) - North America Market Analysis (Current and Future) by Geographic Region for Canada and United States in US$ Million (Graphical Representation Included)

Exhibit 43: BSE Post Mortem Testing (2006, 2009 and 2012) - Percentage Breakdown of North American Market Value by Geographic Region for Canada and United States (Graphical Representation Included)

US Beef Consumption

Exhibit 44: US Beef Market (2002-2007) - Consumption in Billion Pounds (Graphical Representation Included)

US Beef Production

Exhibit 45: US Beef Market (2002-2006) - Production in Billion Pounds (Commercial Carcass Weight) (Graphical Representation Included)

US Beef Exports

Exhibit 46: US Beef Market (2002 - 2007) - Exports in Million Pounds (Commercial Carcass Weight) (Graphical Representation Included)

Exhibit 47: US Beef Market (2002-2007) - Exports in US$ Million (Graphical Representation Included)

South Korea Resumes US Beef Imports

US Packers Consider Re-entry into South Korean Beef Market

Mexico to Resume Trade with US Dairy Heifers

BSE Cases Reported in the US

Only 10 Percent of Cows to be tested for BSE in the US from August

US Lifts Ban on Aged Cattle Imports from Canada

Canadian Beef Markets

Exhibit 48: Canadian Animal Market (2002-2007) -Exports by Beef Products and Live Animal in CAN$ Million (Graphical Representation Included)

Exhibit 49: Canadian Cattle Market (2002 - 2007) - Exports to the US in Number of Head (Graphical Representation Included)

New Incidence of BSE in Canada Reignites US Import Struggle

Exhibit 50: Canadian Beef and Veal Market (2002-2007) - Exports to the US in Billion Pounds (Graphical Representation Included)

Bison in Demand after BSE Crisis

Confirmed BSE Cases in North America

Exhibit 51: Number of Confirmed BSE cases in United States and Canada

1997 Canada Feed Ban

Prevalence of BSE in Canada

$39.8 Million to Alberta for New Feed Regulation Implementation

New Regulations for Animal Feed in Canada

Beef Industry in Canada Granted Class Action Suit of Compensation

Safer Designation for Canadian Cattle from World Organization for Animal Health

New Network of Excellence Centers to Study Prion Diseases

Control Measures to Prevent Spread of BSE

Control Measures to Prevent Transmission of BSE to Human

Canada Amends BSE Infection Control Regulations for US Imports

Exhibit 52: BSE Cases Diagnosed in North America (1993-2007)

Exhibit 53: List of Major Companies in North America

B. EUROPE

European Cattle Demographics

Exhibit 54: European Cattle Population (2000-2006) - by Geographic Regions for UK, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe in Million Head (Graphical Representation Included)

Analysis by Prion Deactivation Technologies

Exhibit 55: Prion Deactivation Technologies (2005-2012) - European Market Analysis (Current and Future) by Geographic Region for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 56: Prion Deactivation Technology (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe

Analysis by Prion Reduction Filters

Exhibit 57: Prion Reduction Filters (2005-2012) - European Market Analysis (Current and Future) by Geographic Regions for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 58: Prion Reduction Filters (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe

Analysis by BSE Post Mortem Testing

Exhibit 59: BSE Post Mortem Testing (2005-2012) - European Market Analysis (Current and Future) by Geographic Regions for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe in US$ Million (Graphical Representation Included)

Exhibit 60: BSE Post Mortem Testing (2006, 2009 and 2012) - Percentage Breakdown of European Market Value by Geographic Region for United Kingdom, France, Ireland, Portugal, Switzerland, Germany and Rest of Europe.

Exhibit 61: Number of Confirmed BSE cases in Europe by Geographic Regions: United Kingdom, France, Ireland, Portugal, Switzerland, Germany (2003-2007)

BSE Cases in the United Kingdom

Measures Taken by United Kingdom to Control BSE

Germany to Modify BSE Testing Regulations

Exhibit 62: List of Major Companies in Europe

C. JAPAN

Analysis by Prion Deactivation Technologies

Exhibit 63: Prion Deactivation Technologies (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 64: Prion Reduction Filters (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 65: BSE Post Mortem Testing (2005-2012) - Japanese Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Exhibit 66: Number of Confirmed BSE Cases in Japan (Graphical Representation Included)

BSE Cases Reported in Japan

Health Ministry Bans Blood Donations in Japan

A New Amendment Proposed by USDA on Import of Boneless Beef from Japan

Japan Re-enforces US Beef Ban

D. REST OF WORLD

Analysis by Prion Deactivation Technologies

Exhibit 67: Prion Deactivation Technologies (2005-2012) - Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included)

Analysis by Prion Reduction Filters

Exhibit 68: Prion Reduction Filters (2005-2012) - Rest of World Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

Analysis by BSE Post Mortem Testing

Exhibit 69: BSE Post Mortem Testing (2005-2012) - Rest of World Market Analysis (Current and Future) in US$ Million (Graphical Representation Included)

5. The Industry Outlook

V. CORPORATE DIRECTORY

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.